Is SELLAS Life Sciences Group, Inc. (SLS) a Buy, Sell, or Hold?
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$13.39 USD
$0.77 (6.1%)
- Volume
- 6.07M
- Average Volume
- 9.2M
- Market Capitalization
- $2.49B
- P/E Ratio
- -58.65
- Dividend Yield
- 0.00%
- Price Target
- $25.00
- Year High
- $15.88
- Year Low
- $1.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $17.22
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Angelos Stergiou |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SLS |
| CUSIP | 81642T209 |
| CIK | 0001390478 |
| Web | https://www.sellaslifesciences.com |
| Phone | 646 200 5278 |
| Currency | USD |
| Employees | 13 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 17.22 |
| Quick Ratio | 17.22 |
| Cash Ratio | 16.60 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.16 |
| Price / Cash Flow | -88.44 |
| Price / Book | 21.50 |
Price Target and Rating
| Average Stock Price Forecast | $25.00 |
| High Stock Price Forecast | $25.00 |
| Low Stock Price Forecast | $25.00 |
| Forecast Upside/Downside | -46.44% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.25 |
| Trailing P/E Ratio | -58.65 |
| PEG Ratio | -1.00 |
| P/E Growth | -1.00 |
| Net Income | $-26.86M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -47.12% |
| Return on Assets | -25.80% |
Financials Score
| AltmanZ Score | 206.65 |
| Piotroski Score | 2.00 |
| Working Capital | 104.71M |
| Total Assets | 114.18M |
| Ebit | -29.46M |
| Market Cap | 2.37B |
| Total Liabilities | 6.76M |
Poll Results
About SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Slo ... an Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
2026-07-14 15:06:56
SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline should not be interpreted as evidence of failure or success, given its event-driven design and recent protocol amendments. FDA-approved unlimited dosing and continued management confidence add nuance, but only final data will determine REGAL's outcome.
SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall
2026-07-08 11:09:35
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Wednesday as investors take profits following the stock's strong longer-term uptrend, with broader risk appetite also softer across equities.
SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?
2026-06-30 09:39:51
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Tuesday as traders digest the recent breakout run and early profit-taking shows up even with momentum still elevated from the company's latest corporate update.
Amentum Wins NASA'S COSMOS Contract to Advance Spaceflight Mission Operations
2026-06-30 09:00:00
[url="]Amentum[/url] (NYSE: AMTM), a global leader in advanced engineering and technology solutions, has been awarded NASA's Consolidated Spaceflight Mission O
Sellas Life Sciences: The AML Platform Is More Interesting Than The Binary Event
2026-06-27 04:25:06
SELLAS Life Sciences is advancing a dual-path AML franchise with GPS nearing pivotal Phase 3 REGAL readout and SLS009 progressing in high-risk AML settings. SLS has strengthened its cash position to $135.8 million, providing a multi-year runway and flexibility ahead of critical data and potential commercialization. The REGAL trial's delayed event count sustains optimism for GPS efficacy in CR2 AML, with topline results imminent and BLA preparation underway.
What's driving SLS stock higher today and what comes next?
2026-06-26 12:30:49
Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and protection. Specifically, the board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.
SELLAS Stock Hits New Highs: What's Happening Today?
2026-06-26 10:54:17
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are pushing higher Friday morning, adding to Thursday's strong rally.
Why SELLAS Life Sciences Stock Is Surging Thursday
2026-06-25 14:07:40
Shares of SELLAS Life Sciences Group Inc. (NASDAQ:SLS) are rallying sharply Thursday, hitting a fresh 52-week high of $11.06, up over 16% in midday trading. The clinical-stage biopharmaceutical company is experiencing a massive surge in volume following a regulatory filing.
Frequently Asked Questions
-
What is the current SELLAS Life Sciences Group, Inc. (SLS) stock price?
-
SELLAS Life Sciences Group, Inc.(NASDAQ:SLS) stock price is $13.39 in the last trading session. During the trading session, SLS stock reached the peak price of $15.88 while $1.39 was the lowest point it dropped to. The percentage change in SLS stock occurred in the recent session was 6.1% while the dollar amount for the price change in SLS stock was $0.77.
-
SLS's industry and sector of operation?
-
The NASDAQ listed SLS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SLS?
-
Angelos Stergiou | Founder, President, Chief Executive Officer & Director
Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC & Quality
John Thomas Burns | Senior Vice President & Chief Financial Officer
Stacy Yeung | VP, General Counsel & Corporate Secretary
Dragan Cicic | Senior Vice President & Chief Development Officer -
How many employees does SLS have?
-
Number of SLS employees currently stands at 13. SLS operates from 7 Times Square, New York, NY 10036, US.
-
Link for SLS official website?
-
Official Website of SLS is: https://www.sellaslifesciences.com
-
How do I contact SLS?
-
SLS could be contacted at phone #646 200 5278 and can also be accessed through its website. SLS operates from 7 Times Square, New York, NY 10036, US.
-
How many shares of SLS are traded daily?
-
The average number of SLS shares traded daily for last 3 months was 9.2M.
-
What is the market cap of SLS currently?
-
The market value of SLS currently stands at $2.49B with its latest stock price at $13.39